Literature DB >> 9169401

Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis.

P M Rothwell1, Z McDowell, C K Wong, P J Dorman.   

Abstract

OBJECTIVES: To compare the judgments of clinicians on which domains of health in the short form questionnaire (SF-36) would be most important to patients with multiple sclerosis with the opinions of patients themselves; to compare assessment of physical disability in multiple sclerosis by a clinician using Kurtzke's expanded disability status scale and a non-clinically qualified assistant using the Office of Population Census and Surveys' (OPCS) disability scale with self assessment of disability and other domains of health related quality of life by patients using the SF-36 and the EuroQol questionnaire; and to compare the scores of patients for each domain of the SF-36 with control data matched for age and sex.
DESIGN: Cross sectional study.
SETTING: Clinical department of neurology, Edinburgh.
SUBJECTS: 42 consecutive patients with multiple sclerosis attending a neurology outpatient clinic for review or a neurology ward for rehabilitation. MAIN OUTCOME MEASURES: Scores on the SF-36; EuroQol; Kurtzke's expanded disability status scale; the OPCS disability scale.
RESULTS: Patients and clinicians disagreed on which domains of health status were most important (chi 2 = 21, df = 7, P = 0.003). Patients' assessment of their physical disability using the physical functioning domain of the SF-36 was highly correlated with the clinicians' assessment (r = -0.87, P < 0.001) and the non-clinical assessment (r = -0.90, P < 0.001). However, none of the measures of physical disability correlated with overall health related quality of life measured with EuroQol, Quality of life correlated with vitality, general health, and mental health in the SF-36, each of which patients rated as more important than clinicians and for each of which patients scored lower than the controls.
CONCLUSIONS: Patients with multiple sclerosis and possibly those with other chronic diseases are less concerned than their clinicians about physical disability in their illness. Clinical trials in multiple sclerosis should assess the effect of treatment on the other elements of health status that patients consider important, which are also affected by the disease process, are more closely related to overall health related quality of life, and may well be adversely affected by side effects of treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9169401      PMCID: PMC2126825          DOI: 10.1136/bmj.314.7094.1580

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  135 in total

Review 1.  Subjective outcome measurement--a primer.

Authors:  M P Tully; J A Cantrill
Journal:  Pharm World Sci       Date:  1999-06

Review 2.  Neurological rehabilitation: from mechanisms to management.

Authors:  A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

3.  Who should measure quality of life?

Authors:  J Addington-Hall; L Kalra
Journal:  BMJ       Date:  2001-06-09

Review 4.  The significance of quality of life in health care.

Authors:  Robert M Kaplan
Journal:  Qual Life Res       Date:  2003       Impact factor: 4.147

5.  A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

Authors:  Pietro Annovazzi; Valentina Tomassini; Benedetta Bodini; Laura Boffa; Massimiliano Calabrese; Eleonora Cocco; Cinzia Cordioli; Giovanna De Luca; Giovanni Frisullo; Antonio Gallo; Simona Malucchi; Damiano Paolicelli; Ilaria Pesci; Marta Radaelli; Paolo Ragonese; Luca Roccatagliata; Carla Tortorella; Marco Vercellino; Valentina Zipoli; Claudio Gasperini; Mariaemma Rodegher; Claudio Solaro
Journal:  Neurol Sci       Date:  2012-03-11       Impact factor: 3.307

6.  Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II).

Authors:  Francesco Patti; Maria Pia Amato; Maria Trojano; Stefano Bastianello; Maria Rosalia Tola; Orietta Picconi; Sabina Cilia; Salvatore Cottone; Luigi M E Grimaldi
Journal:  Qual Life Res       Date:  2011-09-28       Impact factor: 4.147

7.  Unmet needs of patients feeling severely affected by multiple sclerosis in Germany: a qualitative study.

Authors:  Maren Galushko; Heidrun Golla; Julia Strupp; Ute Karbach; Claudia Kaiser; Nicole Ernstmann; Holger Pfaff; Christoph Ostgathe; Raymond Voltz
Journal:  J Palliat Med       Date:  2014-02-14       Impact factor: 2.947

8.  Descriptive survey of non-commercial randomised controlled trials in the United Kingdom, 1980-2002.

Authors:  Iain Chalmers; Cath Rounding; Kate Lock
Journal:  BMJ       Date:  2003-11-01

9.  Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment.

Authors:  Peter M ten Klooster; Martine M Veehof; Erik Taal; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

Review 10.  The effect of deep brain stimulation on quality of life in movement disorders.

Authors:  A Diamond; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.